What 100 Percent Margin Assessment Actually Means, and Why It Drives the Mohs Cure Rate

Patients researching skin cancer treatment often encounter the same claim: Mohs micrographic surgery offers cure rates of 97 to 99 percent for primary basal cell and squamous cell carcinomas, compared with roughly 90 to 95 percent for standard excision. Those numbers are broadly supported by decades of outcome data, but the reason behind them is rarely explained well. The advantage is not that Mohs surgeons cut more skillfully. It is that Mohs uses a fundamentally different method of checking whether the cancer is gone.

The bread loaf problem For an independent overview, see Mohs micrographic surgery: how margin checking works.

When a surgeon performs a standard excision, the specimen goes to a pathology lab, where it is typically processed using a technique called bread loafing. The tissue is cut into vertical slices at intervals, often every 2 to 4 millimeters, and a thin section from each slice is examined under a microscope. The name is apt: imagine slicing a loaf of bread and inspecting only a few slices to decide whether the whole loaf is free of mold.

The math here matters. Bread loafing samples only a small fraction of the actual surgical margin, often estimated at well under 5 percent of the total margin surface. If a tumor sends out a thin strand of cancer cells between two sampled slices, the pathology report can read "margins clear" while cancer remains in the patient. This is not lab error. It is a sampling limitation built into the technique. Basal cell carcinomas, in particular, can grow in narrow, root-like extensions that slip between sections, which is one reason infiltrative and morpheaform subtypes recur more often after standard excision.

How Mohs changes the geometry

Mohs processing turns the specimen inside out, almost literally. Instead of vertical slices through the middle of the tissue, the Mohs technician flattens the specimen so that the entire deep surface and the entire peripheral edge lie in one plane. Horizontal frozen sections are then cut from that plane. The result is that the surgeon examines essentially 100 percent of the true surgical margin, not a sampled fraction of it.

Because the surgeon also acts as the pathologist and maps each specimen against the wound, a positive margin can be traced back to its exact location on the patient. The surgeon then removes another thin layer only where cancer persists, sparing healthy tissue elsewhere. This cycle repeats until the entire margin is clear. The high cure rate is a direct consequence of this complete margin evaluation, and the tissue-sparing benefit is a consequence of the mapping.

What frozen sections can and cannot do

Mohs relies on frozen sections read in real time, which is what allows same-day margin control. Frozen sections are excellent for basal cell and squamous cell carcinoma, where tumor cells are usually easy to distinguish from normal skin. They are less reliable for some tumors. Melanoma cells, for example, can be difficult to identify on standard frozen sections, which is why conventional Mohs for invasive melanoma remains debated and why some centers use immunostains such as MART-1 to make melanocytes visible during surgery. When you hear that Mohs is "not for every skin cancer," this is a large part of the mechanism behind that statement.

Why standard excision still has a place

None of this makes standard excision obsolete. For small, well-defined, low-risk tumors on the trunk or limbs, standard excision with appropriate margins works very well, costs less, and takes less time. The appropriate use criteria published jointly by major dermatology and Mohs surgery organizations exist precisely to sort this out: Mohs earns its added complexity where the stakes of a missed margin are highest. That means tumors on the face, ears, nose, lips, eyelids, hands, feet, and genitals, recurrent tumors, aggressive histologic subtypes, tumors larger than about 2 centimeters in high-risk areas, and cancers in immunosuppressed patients.

The practical takeaway

If a clinician recommends Mohs, the honest justification is not "it is the best surgery." It is "this tumor's location, subtype, or history makes complete margin assessment worth the extra time." If a clinician recommends standard excision, that is often equally sound reasoning: the tumor's risk profile does not justify the added resources of intraoperative margin mapping.

One useful question for any patient weighing the options: how will the margins be evaluated, and what percentage of the margin will actually be examined? The answer to that question, more than any cure rate quoted in a brochure, explains the real difference between the two procedures. The 99 percent figure is not magic. It is what happens when you check the whole loaf instead of a few slices.

Related reading: What your skin biopsy report means before Mohs surgery.